Can Vimpat and Depakote Be Used Together?
Yes, a patient can be prescribed both lacosamide (Vimpat) and valproic acid (Depakote) together—there is no pharmacokinetic interaction between these medications, and they are commonly combined in clinical practice for seizure management. 1
Evidence Supporting Combination Therapy
No Pharmacokinetic Interaction
A dedicated drug-drug interaction study in healthy volunteers demonstrated that lacosamide and valproic acid have no relevant pharmacokinetic interaction 1. When administered together:
- Area under the curve (AUC) and maximum concentration (Cmax) remained within the 80-125% equivalence range
- No changes in absorption rate, terminal half-life, or time to maximum concentration occurred
- Point estimates were 104% and 101% for valproic acid, and 100% and 101% for lacosamide
Clinical Use in Status Epilepticus
Both medications are recognized as appropriate second-line agents for status epilepticus. Emergency physicians may administer intravenous valproate in patients with refractory status epilepticus who have failed benzodiazepines 2. Similarly, lacosamide has demonstrated comparable efficacy to levetiracetam and valproate as second-line therapy in adult status epilepticus 3.
Synergistic Effects in Animal Models
Interestingly, while one animal study showed sub-additive effects when combining lacosamide with lamotrigine and valproate in a three-drug combination 4, another study demonstrated synergistic or additive anticonvulsant effects when lacosamide was combined with various antiepileptic drugs including valproate 5. The clinical relevance of these preclinical findings remains uncertain.
Important Caveats and Monitoring
Rare Case Reports of Toxicity
One isolated case report described valproic acid toxicity in the presence of lacosamide 6, though this has not been consistently reproduced. The patient recovered fully after withdrawal of both medications. This represents an extremely rare occurrence but warrants awareness.
Potential Level Changes
One small case series reported that lacosamide can lower valproic acid serum levels 7, though the clinical significance and mechanism remain unclear. This contradicts the formal pharmacokinetic study showing no interaction 1.
Monitoring Recommendations
When combining these medications:
- Monitor valproic acid levels if seizure control changes after adding lacosamide
- Watch for signs of valproic acid toxicity (tremor, confusion, hyperammonemia, encephalopathy) 8
- Be aware of valproate's extensive adverse effect profile including hepatotoxicity, pancreatitis, thrombocytopenia, and teratogenicity 8
- Monitor for lacosamide-related bradycardia, especially in patients with cardiac conduction abnormalities
Clinical Bottom Line
The combination of Vimpat and Depakote is pharmacologically sound and clinically appropriate for patients requiring polytherapy for seizure control. The formal pharmacokinetic study showing no interaction 1 outweighs isolated case reports. However, maintain standard monitoring practices for both medications, particularly valproic acid levels and clinical response, as individual patient variability can occur.